新型囊性纤维化治疗方法的效果和价值。
The effectiveness and value of novel treatments for cystic fibrosis.
机构信息
Division of General Internal Medicine, University of California, San Francisco.
School of Public Health, University of Minnesota.
出版信息
J Manag Care Spec Pharm. 2021 Feb;27(2):276-280. doi: 10.18553/jmcp.2021.27.2.276.
Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, America's Health Insurance Plans, Anthem, Allergan, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare. Seidner, Rind, and Pearson are employed by ICER. Tice reports contracts to his institution, University of California, San Francisco, from ICER during the conduct of this study. Wherry has nothing to disclose.
本摘要的资助由 Arnold Ventures、加州医疗保健基金会、哈佛朝圣者健康保健、Kaiser 基金会健康计划提供给临床和经济评估研究所（ICER），这是一个独立评估医疗保健干预措施价值证据的组织。ICER 的年度政策峰会由 Aetna、美国健康保险计划、Anthem、Allergan、Alnylam、阿斯利康、Biogen、加州蓝盾、勃林格殷格翰、Cambia 健康服务、CVS、Editas、Express Scripts、基因泰克/罗氏、葛兰素史克、哈佛朝圣者、医疗保健服务公司、HealthFirst、Health Partners、强生（杨森）、Kaiser 永久、利奥制药、美纳里克斯、默克、诺华、国家制药理事会、辉瑞、Premera、Prime Therapeutics、Regeneron、赛诺菲、Spark Therapeutics 和联合健康保险公司赞助。Seidner、Rind 和 Pearson 受雇于 ICER。Tice 在进行这项研究期间向他的机构加州大学旧金山分校报告了来自 ICER 的合同。Wherry 没有需要披露的信息。
Zotero 插件